Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs SYSCO Corporation (SYY) Price & Performance

ADMA Biologics IncTrade
SYSCO CorporationTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs SYSCO Corporation — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while SYSCO Corporation trades at $84.5 (market cap $40.32B). The key difference: SYSCO Corporation is far larger — about 18.2× ADMA Biologics Inc's market cap, and SYSCO Corporation pays a 2.61% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMASYY
Market Cap
$2.22B$40.32B
Sector
HealthConsumer Staples
52-Week High
$20.38$91.16
52-Week Low
$7.60$69.30
Enterprise Value
$2.29B$53.50B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.

Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.

SYSCO Corporation

Sysco (SYY) trades at $84.73, up 1.03% today, with a bullish technical signal from moving averages and a consensus analyst price target of $88.25. The company reported strong Q4 2026 earnings, beating EPS estimates with $1.53 versus $1.51 expected, driven by U.S. foodservice volume growth and cost efficiencies. Revenue reached $81.37 billion in 2025, with net income of $1.83 billion, though profit margins remain thin at 2.08%. Recent news highlights CEO discussions on CNBC and operational initiatives, including AI-driven efficiencies.

The outlook for SYY is positive, supported by earnings beats, steady cash flow, and analyst optimism, but risks include competitive pressures, supply chain disruptions, and macroeconomic uncertainty. Upside potential exists if the company maintains volume growth and margin improvements, but investors should monitor debt levels and food safety issues highlighted in recent reports.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About SYSCO Corporation

Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.

Read more on SYY